Blood pressure-lowering drugs: essential therapy for some patients with normal blood pressure

References

• Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360, 1903–1913 (2002).
   PubMed Web of Science ®Google Scholar
• ••Meta-analysis summarizing the results of alarge body of human investigations on the risks of disease. It establishes, beyond any reasonable doubt, that the real normal blood pressure is similar to those observed in nonacculturated populations — below 115/75 mmHg.
   Google Scholar
• Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mmHg. J. Am. Med. Assoc. 202, 1028–1034 (1967).
   PubMed Web of Science ®Google Scholar
• •This trial is one of the foundations of modern medicine, demonstrating the strong benefit derived from the drug treatment of patients with severe hypertension.
   Google Scholar
• Fuchs FD, Klag MJ, Whelton PK. The classics: a tribute to the 50th anniversary of the randomized clinical trial. J. Clin. Epidem. 53, 335–342 (2000).
   PubMed Web of Science ®Google Scholar
• Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension II. Results in patients with diastolic blood pressures averaging 90 through 114 mmHg. J. Am. Med. Assoc. 213, 1143–1152 (1970).
   Google Scholar
• Collins R, Peto R, MacMahon S et al. Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomized drug trials in their epidemiological context. Lancet 335, 827–838 (1990).
   PubMed Web of Science ®Google Scholar
• •Classical meta-analysis of the first clinical trials that demonstrated the benefits of blood pressure-lowering drugs at a wide range of blood pressure values.
   Google Scholar
• MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults. Br Med. J. 304, 405–412 (1992).
   PubMed Web of Science ®Google Scholar
• Dahliif B, Lindholm LH, Hansson L, Schersten B, Ekbom T, Wester PO. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 338, 1281–1285 (1991).
   PubMedGoogle Scholar
• SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. J Am. Med Assoc. 265, 3255–3264 (1991).
   PubMed Web of Science ®Google Scholar
• Staessen JA, Fagard R, Thijs L et al Randomized, double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 350, 757–764 (1997).
   PubMed Web of Science ®Google Scholar
• Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet 358, 1305–1315 (2001).
   PubMed Web of Science ®Google Scholar
• •Creative, systematic review of the evidence, demonstrating the close relationship between the intensity of blood pressure lowering and the reduction in the incidence of major cardiovascular events.
   Google Scholar
• Staessen JA, Wang JG, Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until March 2003.j Hypertens. 21, 1055–1076 (2003).
   Web of Science ®Google Scholar
• The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic. The Antihypertensive and Lipid-Lowering Treatment to prevent Heart Attack Trial (ALLHAT). J Am. Med Assoc. 288, 2981–2997 (2002).
   PubMed Web of Science ®Google Scholar
• ••Landmark trial that showed that diuretics(old and inexpensive antihypertensive drugs) are the most efficacious agents for starting the treatment of hypertension in a wide range of racial, age, and medical-condition groups.
   Google Scholar
• The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl. J. Med. 342, 145–153 (2000).
   PubMed Web of Science ®Google Scholar
• The Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 355, 253–259 (2000).
   PubMedGoogle Scholar
• Svensson P, Faire U, Sleight P, Yusuf S, Ostergren J. Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE substudy. Hypertension 38, E28—E32 (2001).
   PubMed Web of Science ®Google Scholar
• PROGRESS Collaborative Group. Randomized trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischemic attack. Lancet 358, 1033–1041 (2001).
   PubMed Web of Science ®Google Scholar
• •Results of this trial should be urgently incorporated into clinical practice; the use of a diuretic and an ACE inhibitor is the most efficacious approach to prevent a new stroke in patients who have recovered from a previous one.
   Google Scholar
• Fox KM. EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomized, double-blind, placebo-controlled, multicenter trial (the EUROPA study). Lancet 362, 782–788 (2003).
   PubMed Web of Science ®Google Scholar
• The SOLVD investigators. Effect of enalapril on mortality and development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl. J. Med. 327, 685–691 (1992).
   PubMed Web of Science ®Google Scholar
• The SOLVD investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl. J. Med. 325, 669–677 (1991).
   PubMedGoogle Scholar
• •One of several clinical trials that demonstrates the benefit of the use of angiotensin-converting enzyme inhibitors in patients with heart failure.
   Google Scholar
• Pfeffer MA, Braunwald E, Moye LA et al Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival And Ventricular Enlargement trial. The SAVE Investigators. N Engl J. Med 327, 669–677 (1992).
   PubMed Web of Science ®Google Scholar
• Packer M, Poole-Wilson PA, Armstrong PW et al Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation 100,2312–2318 (1999).
   PubMed Web of Science ®Google Scholar
• Cohn JN, Johnson G, Ziesche S et al A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl Med 325, 303–310 (1991).
   PubMed Web of Science ®Google Scholar
• CIBIS Investigators and Committees. A randomized trial of 13-blockade in heart failure. The Cardiac Insufficiency BIsoprolol Study (CIBIS). Circulation 90, 1765–1773 (1994).
   PubMed Web of Science ®Google Scholar
• Packer M, Bristow MR, Cohn JN et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US Carvedilol Heart Failure Study Group. N Engl J. Med 334, 1349–1355 (1996).
   PubMed Web of Science ®Google Scholar
• Packer M, Coats AJS, Fowler MB et al. Effect of carvedilol on survival in severe chronic heart failure. N Eng1J. Med. 344, 1651–1658 (2001).
   Google Scholar
• MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure. MEtoprolol CR/XL Randomized Intervention Trial in congestive Heart Failure (MERIT-HF). Lancet 353, 2001–2007 (1999).
   PubMed Web of Science ®Google Scholar
• Poole-Wilson PA, Swedberg K, Cleland JG et al, and the Carvedilol Or Metoprolol European Trial Investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET) randomized controlled trial. Lancet 362, 7–13 (2003).
   PubMed Web of Science ®Google Scholar
• Pitt B, Zannad F, Remme \X/J- et al The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aMactone evaluation study investigators. N Engl J. Med 341, 709–717 (1999).
   PubMed Web of Science ®Google Scholar
• Packer M, O'Connor CM, Ghali JK et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl. Med. 335, 1107–1114 (1996).
   PubMed Web of Science ®Google Scholar
• Psaty BM, Lumley T, Furberg CD et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. J. Am. Med. Assoc. 289, 2534–2544 (2003).
   PubMed Web of Science ®Google Scholar
• •New approach to the evidence, showing the advantage of diuretics over other classes of blood pressure-lowering drugs in the prevention of various cardiovascular events.
   Google Scholar